Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
CANNANNEW REPORT

Preliminary data showed ANEB-001 reduced effects of a 30 mg dose of THC Delayed dosing of ANEB-001 rapidly reversed pre-existing THC effects Full PK, PD, and safety data expected by end of 1Q2023 Company targeting an End of Phase 2A meeting with FDA in the first half of 2023 AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: […]

Excerpt only …
READ MORE BELOW
Source : Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.